Personal profile
Research Interests
Kræftforskning og gigt
Fingerprint
Dive into the research topics where Lene Egedal Johansen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Researchers
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer
Alves, C. L., Karimi, L., Terp, M. G., Jakobsen, M. K., Zhou, F. H., Policastro, B., Nissen, N., Johansen, L. E., Ravnsborg, T., Eshraghi, L., Tamboowala, S., Jensen, O. N., Lim, E. & Ditzel, H. J., 17. Dec 2025, In: Science Translational Medicine. 17, 829, p. eadp5088Research output: Contribution to journal › Journal article › Research › peer-review
-
Targeting EMT-driven metastatic breast cancer with mitotic inhibitors
Alves, C. M. L., Policastro, B., Nissen, N., C. Mohamed, H., Roble, Y. M., Johansen, L. E., Jakobsen, M. K. & Ehmsen, S., 15. May 2025.Research output: Contribution to conference without publisher/journal › Poster › Research
-
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
Kindt, C. K., Ehmsen, S., Traynor, S., Policastro, B., Nissen, N., Jakobsen, M. K., Hundebøl, M. F., Johansen, L. E., Bak, M., Arbajian, E., Staaf, J., Ditzel, H. J. & Alves, C., 2024, In: Frontiers in Oncology. 14, 15 p., 1497093.Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile40 Downloads (Pure) -
Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Alves, C. M. L., Nissen, N., Policastro, B., Kristensen, N., Rosengren, F., Johansen, L. E., Staaf, J. & Ditzel, H. J., 9. Oct 2023.Research output: Contribution to conference without publisher/journal › Poster › Research
Open Access -
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
Karimi, L., Alves, C. L., Terp, M. G., Tuttolomondo, M., Portman, N., Ehmsen, S., Johansen, L. E., Bak, M., Lim, E. & Ditzel, H. J., Jun 2023, In: Cancer Communications. 43, 6, p. 720-725Research output: Contribution to journal › Comment/debate › Research › peer-review
Open AccessFile71 Downloads (Pure)